JP1302 dihydrochloride|cas:1259314-65-2|西域试剂

JP1302 dihydrochloride,99.62%

产品编号：Bellancom-103213| CAS NO：1259314-65-2| 分子式：C₂₄H₂₆Cl₂N₄| 分子量：441.40

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-103213	￥1000.00	杭州北京（现货）
Bellancom-103213	￥1500.00	杭州北京（现货）
Bellancom-103213	￥4800.00	杭州北京（现货）
Bellancom-103213	￥7500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

JP1302 dihydrochloride

产品介绍

JP1302 dihydrochloride 是选择性的、高亲和力的 α_2C 肾上腺受体 (α_2C-adrenoceptor) 的拮抗剂，其对人类 α_2C 受体的 K_b 值为 16 nM，K_i 为 28 nM。JP1302 dihydrochloride 具有抗抑郁和类抗精神病作用。JP1302 dihydrochloride 可用于神经精神障碍和肾功能障碍的研究。

生物活性

JP1302 dihydrochloride is a potent, selective, high affinity antagonist of the α_2C-adrenoceptor, with a K_b of 16 nM and a K_i of 28 nM for the human α_2C-receptor. JP1302 dihydrochloride shows antidepressant and antipsychotic-like effects. JP1302 dihydrochloride can be used for neuropsychiatric disorders and renal dysfunction research.

体外研究

JP1302 shows about 100-fold higher affinity than for α_2A or α_2B.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

JP1302 (1-10 μmol/kg) decreases immobility time in the FST to a level similar to that seen with 10-30 μmol/kg of the antidepressant Desipramine (HY-B1272A).
JP1302 (5 μmol/kg, once) is capable of complete reversal of the impairment in PPI induced in Sprague-Dawley rats by the psychotomimetic NMDA receptor antagonist, phencyclidine and similar results are found in Wistar rats.
JP1302 (3 mg/kg, IV, once) significantly ameliorates renal dysfunction.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague Dawley rats (8 weeks old)
Dosage:	3 mg/kg
Administration:	IV, pre-treatment: administered 5 min before the induction of ischemia, post-treatment: injected 45 min after the initiation of reperfusion
Result:	Significantly ameliorated renal dysfunction in the rats at 24 h after reperfusion. post-ischemic administration of JP-1302 significantly ameliorated renal dysfunction, histological damage and reduced apoptotic cells and pro-inflammatory cytokine mRNA expression.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague Dawley rats (8 weeks old)
Dosage:	3 mg/kg
Administration:	IV, pre-treatment: administered 5 min before the induction of ischemia, post-treatment: injected 45 min after the initiation of reperfusion
Result:	Significantly ameliorated renal dysfunction in the rats at 24 h after reperfusion. post-ischemic administration of JP-1302 significantly ameliorated renal dysfunction, histological damage and reduced apoptotic cells and pro-inflammatory cytokine mRNA expression.

性状

Solid

溶解性数据

In Vitro:

H₂O : 12.5 mg/mL (28.32 mM; Need ultrasonic)

DMSO : 5 mg/mL (11.33 mM; ultrasonic and adjust pH to 5 with NaOH)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.2655 mL	11.3276 mL	22.6552 mL
5 mM	0.4531 mL	2.2655 mL	4.5310 mL
10 mM	0.2266 mL	1.1328 mL	2.2655 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶